Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL-Reference-Cited by-同舟云学术

Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL

Published:2015-02-26 Issue:9 Volume:125 Page:1444-1451
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Appelmann Iris¹,Rillahan Cory D.¹,de Stanchina Elisa²,Carbonetti Gregory²,Chen Chong¹,Lowe Scott W.¹³,Sherr Charles J.¹³⁴^ORCID

Affiliation:

1. Cancer Biology & Genetics Program, and

2. Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY; and

3. Howard Hughes Medical Institute, and

4. Department of Tumor Cell Biology, St. Jude Children’s Research Hospital, Memphis, TN

Abstract

Key Points In a Ph+ ALL mouse model, dasatinib inhibition of the BCR-ABL kinase resensitizes residual leukemic B cells to Janus kinase inhibition. Dasatinib, ruxolitinib, and dexamethasone together limit emergence of dasatinib-resistant BCR-ABL mutants and extend long-term survival.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/125/9/1444/1388339/1444.pdf

Reference37 articles.

1. The BCR-ABL story: bench to bedside and back.;Wong;Annu Rev Immunol,2004

2. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.;Ravandi;Blood,2010

3. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.;Foà;Blood,2011

4. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.;Ravandi;Blood,2013

5. The INK4-ARF (CDKN2A/B) locus in hematopoiesis and BCR-ABL-induced leukemias.;Williams;Cold Spring Harb Symp Quant Biol,2008

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DEX‐Induced SREBF1 Promotes BMSCs Differentiation into Adipocytes to Attract and Protect Residual T‐Cell Acute Lymphoblastic Leukemia Cells After Chemotherapy;Advanced Science;2023-04-18

2. Puppet masters of B‐cell progenitor acute lymphoblastic leukemia: The preB cell receptor and the interleukin 7 receptor α;European Journal of Immunology;2023-03-09

3. Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia;PLOS ONE;2022-10-04

4. Novel Treatments for Pediatric Relapsed or Refractory Acute B-Cell Lineage Lymphoblastic Leukemia: Precision Medicine Era;Frontiers in Pediatrics;2022-06-23

5. Combined treatment of graft versus host disease using donor regulatory T cells and ruxolitinib;Scientific Reports;2022-05-19